173 related articles for article (PubMed ID: 37532789)
1. A C/ebpα isoform specific differentiation program in immortalized myelocytes.
Garcia-Cuellar MP; Akan S; Slany RK
Leukemia; 2023 Sep; 37(9):1850-1859. PubMed ID: 37532789
[TBL] [Abstract][Full Text] [Related]
2. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract][Full Text] [Related]
3. Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene.
Odaira K; Yasuda T; Okada K; Shimooka T; Kojima Y; Noura M; Tamura S; Kurahashi S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
Cancer Sci; 2023 Mar; 114(3):781-792. PubMed ID: 36341510
[TBL] [Abstract][Full Text] [Related]
4. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
[TBL] [Abstract][Full Text] [Related]
5. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
[TBL] [Abstract][Full Text] [Related]
6. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.
O'Connor C; Lohan F; Campos J; Ohlsson E; Salomè M; Forde C; Artschwager R; Liskamp RM; Cahill MR; Kiely PA; Porse B; Keeshan K
Oncogene; 2016 Oct; 35(40):5272-5281. PubMed ID: 26996668
[TBL] [Abstract][Full Text] [Related]
7. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
9. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
[TBL] [Abstract][Full Text] [Related]
10.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
12. E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.
Pal P; Lochab S; Kanaujiya JK; Kapoor I; Sanyal S; Behre G; Trivedi AK
Cell Death Dis; 2013 Apr; 4(4):e590. PubMed ID: 23598402
[TBL] [Abstract][Full Text] [Related]
13. Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation.
Wang D; Sun T; Xia Y; Zhao Z; Sheng X; Li S; Ma Y; Li M; Su X; Zhang F; Li P; Ma D; Ye J; Lu F; Ji C
Nat Commun; 2023 Oct; 14(1):6907. PubMed ID: 37903757
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
Katzerke C; Madan V; Gerloff D; Bräuer-Hartmann D; Hartmann JU; Wurm AA; Müller-Tidow C; Schnittger S; Tenen DG; Niederwieser D; Behre G
Blood; 2013 Oct; 122(14):2433-42. PubMed ID: 23974200
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
Schmidt L; Heyes E; Grebien F
Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
[TBL] [Abstract][Full Text] [Related]
16. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
17. C/EBPα in normal and malignant myelopoiesis.
Friedman AD
Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
[TBL] [Abstract][Full Text] [Related]
18. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.
Kirstetter P; Schuster MB; Bereshchenko O; Moore S; Dvinge H; Kurz E; Theilgaard-Mönch K; Månsson R; Pedersen TA; Pabst T; Schrock E; Porse BT; Jacobsen SE; Bertone P; Tenen DG; Nerlov C
Cancer Cell; 2008 Apr; 13(4):299-310. PubMed ID: 18394553
[TBL] [Abstract][Full Text] [Related]
19. Insight into the mechanism of AML del(9q) progression: hnRNP K targets the myeloid master regulators CEBPA (C/EBPα) and SPI1 (PU.1).
Rahn K; Abdallah AT; Gan L; Herbrich S; Sonntag R; Benitez O; Malaney P; Zhang X; Rodriguez AG; Brottem J; Marx G; Brümmendorf TH; Ostareck DH; Ostareck-Lederer A; Crysandt M; Post SM; Naarmann-de Vries IS
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):195004. PubMed ID: 38008244
[TBL] [Abstract][Full Text] [Related]
20. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
